The Life Sciences Growth Series: Royalty Monetization Update

Join us for the next edition of the Life Sciences Growth Series where we'll be giving updates on royalty monetization transactions for biopharmaceutical companies.

In this session, partners Andrew Mariniello and Conor Larkin will cover the need-to-know details on how to handle these transactions. Continuing from past sessions, Andrew and Conor will give their insights on key issues for royalty holders and their investors.

TOPICS WILL INCLUDE:

• Traditional versus synthetic royalty monetizations
• Economic factors to consider for royalty holders and investors
• Scoping representations, covenants, and security interests
• UCC, tax, and accounting considerations